Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
Główni autorzy: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Język: | English |
Wydane: |
American Society of Clinical Oncology
2022
|